RecruitingPhase 2NCT04079179

Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders

Studying Erdheim-Chester disease

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Carl Allen
Principal Investigator: Carl E Allen, MD, PhD
Baylor College of Medicine
Intervention: Cobimetinib(drug)
Enrollment: 90 enrolled
Eligibility: All sexes
Timeline: 2021 – 2029

Study locations (12)

Phoenix Children's Hospital, Phoenix, Arizona, United States
Arkansas Children's Hospital, Little Rock, Arkansas, United States
Children's Hospital of Orange County, Orange, California, United States
UCSF Benioff Children's Hospital, San Francisco, California, United States
Children's National Hospital, Washington D.C., District of Columbia, United States
John Hopkins University School of Medicine, Baltimore, Maryland, United States
Dana Farber Cancer Institute, Boston Children's, Boston, Massachusetts, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
NACHO Consortium, Memphis, Tennessee, United States
Children's Medical Center- UTSW, Dallas, Texas, United States
Texas Children's Hospital, Houston, Texas, United States
University of Wisconsin-American Family Children's Hospital, Madison, Wisconsin, United States

Collaborators

Baylor College of Medicine · North American Consortium for Histiocytosis · Genentech, Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04079179 on ClinicalTrials.gov

Other trials for Erdheim-Chester disease

Additional recruiting or active studies for the same condition.

See all trials for Erdheim-Chester disease →

← Back to all trials